New combo attack on stubborn blood cancer
NCT ID NCT04938232
Summary
This study is testing whether adding the drug ipilimumab to the approved drug nivolumab can help control Hodgkin lymphoma that has come back or stopped responding to other treatments. It will involve about 13 adults whose cancer got worse after a prior type of immunotherapy. Participants will first receive ipilimumab alone, and those who don't respond well may then receive the two-drug combination, with treatment lasting up to about two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of Chicago Medicine
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.